ML 10302 is primarily used in research settings as a selective antagonist for serotonin receptors, particularly the 5-HT2C receptor subtype. Its main application lies in neuropharmacological studies where it helps scientists investigate the role of serotonin signaling in behaviors such as appetite regulation, mood, and sleep. Due to its selectivity, it is a valuable tool in distinguishing the effects of 5-HT2C from other serotonin receptor subtypes. It has also been used in preclinical studies to explore potential treatments for psychiatric disorders, including depression, anxiety, and schizophrenia. Additionally, ML 10302 supports research into metabolic and feeding behaviors, making it relevant in studies related to obesity and eating disorders. Its use is currently restricted to laboratory and experimental applications, with no approved clinical use in humans.